Funding for research into the development of new RNA and mRNA based vaccines and therapeutics

Overview

Funding is available for projects that aim to develop a new mRNA-based medicine for human use (either prophylactic or treatment) with a clear pathway for translation. The program is agnostic to disease targets, but candidates must use mRNA technology.

Eligible expenditure includes:

• regulatory and intellectual property fees and charges associated with registering patents or IP
• equipment, consumables and services required for the research activity
• staffing costs related directly to the project.

Check if you can apply

Applicants must be one of the following entity types:

• an incorporated company registered with the Australian Securities and Investment Commission
• an incorporated association
• education body
• public health service
• other incorporated entity approved by the agency.

Additionally, applicants must:

• hold an active Australian business number (ABN)
• have appropriate insurance policies
• comply with any co-contribution requirements
• spend the majority of the grant funding in Victoria
• predominantly conduct and lead the research activities in Victoria.